Analysts Set Expectations for AQST FY2024 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Investment analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for shares of Aquestive Therapeutics in a research report issued to clients and investors on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings of ($0.45) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $17.00 target price on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.47) per share.

A number of other research firms also recently commented on AQST. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Leerink Partners boosted their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research note on Wednesday, November 6th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $11.00.

Aquestive Therapeutics Stock Performance

AQST opened at $3.64 on Thursday. The stock has a market capitalization of $331.89 million, a PE ratio of -8.09 and a beta of 2.62. Aquestive Therapeutics has a one year low of $1.84 and a one year high of $6.23. The business’s 50 day moving average price is $4.74 and its 200 day moving average price is $4.06.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $13.54 million for the quarter, compared to the consensus estimate of $12.69 million. During the same quarter last year, the firm earned ($0.03) EPS.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds have recently bought and sold shares of AQST. Financial Advocates Investment Management increased its stake in Aquestive Therapeutics by 14.7% during the third quarter. Financial Advocates Investment Management now owns 39,000 shares of the company’s stock worth $194,000 after purchasing an additional 5,000 shares during the period. nVerses Capital LLC purchased a new stake in Aquestive Therapeutics during the 3rd quarter worth approximately $28,000. Charles Schwab Investment Management Inc. lifted its holdings in Aquestive Therapeutics by 4.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock worth $1,014,000 after buying an additional 9,268 shares in the last quarter. SG Americas Securities LLC boosted its position in Aquestive Therapeutics by 58.9% in the 3rd quarter. SG Americas Securities LLC now owns 25,619 shares of the company’s stock valued at $128,000 after buying an additional 9,496 shares during the period. Finally, Victory Capital Management Inc. acquired a new position in shares of Aquestive Therapeutics in the second quarter worth $27,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.